Door Opens For Barr To Acquire Pliva As Actavis Bows Out Of Bidding War
This article was originally published in The Pink Sheet Daily
Executive Summary
Hurdles for completing the acquisition still exist for Barr, which must acquire majority of Pliva shares.
You may also be interested in...
Generic Drug Firms Look To Bulk Up With Addition Of Merck KGaA’s Generics Unit
Ranbaxy and Actavis are among the generic drug companies interested in bidding for the $2.32 billion business.
Generic Drug Firms Look To Bulk Up With Addition Of Merck KGaA’s Generics Unit
Ranbaxy and Actavis are among the generic drug companies interested in bidding for the $2.32 billion business.
Generic Drug Firms Look To Bulk Up With Addition Of Merck KGaA's Generics Unit
Ranbaxy and Actavis are two potential bidders vying for Merck KGaA's generics drug unit, an acquisition that would solidify either company as the third largest generics drug maker in the world